Sangamo Announces AAV Capsid Data

Uncategorized

Sangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

BRISBANE, Calif. --(BUSINESS WIRE)--May 2, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted 14 Sangamo abstracts for presentation at the 26 th ASGCT Annual Meeting being held May